Foundation for CAR T-cell therapy Yescarta
Building on their understanding of harnessing the immune system to fight cancer, IRP scientists have sought ways to use genetically altered immune cells called chimeric antigen receptor-expressing T cells (CAR T cells) as an effective form of immunotherapy.
A breakthrough clinical trial led by IRP researchers Steven Rosenberg, M.D., Ph.D., and James Kochenderfer, M.D., showed that CAR T cells that recognize the CD19 receptor protein found on specific immune cells called B cells were useful in the treatment of some types of B-cell malignancies.
This team’s research paved the way for the U.S. Food and Drug Administration’s approval of the first-of-its-kind CAR T-cell therapy – Yescarta – which is now being used to treat adult patients with relapsed or treatment-resistant large B-cell lymphoma, the most common type of non-Hodgkin lymphoma among adults.
Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. (2010). Blood. 116(20):4099-102.
This page was last updated on Friday, January 14, 2022